Program
Genistein-based BIO 300
Also written as “BIO 300 Oral Suspension”, “BIO 300 Oral Powder” and “BIO 300 Capsules”.
Its studies are mostly in Post-Acute COVID-19 Syndrome · Carcinoma, Non-Small-Cell Lung · Radiation Injuries, led by Humanetics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Humanetics | 51 open or running | phase 2since Jul 9, 2015 | Jul 19, 2007 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 19, 2007First study: phase 1 study in Acute Radiation SyndromeFirst studyNCT00504335 · 24 enrolled
- Jul 9, 2015Phase 2 study in Carcinoma, Non-Small-Cell LungNCT02567799 · 21 enrolled · United States
- Jul 17, 2020Phase 2 study in COVID-19NCT04482595 · 50 enrolled · United States
- Nov 19, 2020Phase 1 study in Acute Radiation SyndromeNCT04650555 · 34 enrolled · United States
- Dec 11, 2024Phase 1 study in Acute Radiation SyndromeNCT06741345 · 56 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06741345Acute Radiation Syndrome · United States | 1 | Completed | Aug 15, 2025 | 56 |
| NCT04650555Acute Radiation Syndrome · United States | 1 | Completed | Jul 6, 2021 | 34 |
| NCT04482595COVID-19 · United States | 2 | Active, not recruiting | Jul 31, 2024 | 50 |
| NCT02567799Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Apr 2019 | 21 |
| NCT00504335Acute Radiation Syndrome | 1 | Completed | Sep 2007 | 24 |
How it is read
Names in the registry
- “BIO 300 Oral Suspension”, 3 entries
- “BIO 300 Oral Powder”, 1 entry
- “BIO 300 Capsules”, 1 entry
Conditions, from the studies’ own filings
- Post-Acute COVID-19 Syndrome, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Radiation Injuries, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.